Upadacitinib for treating active non-radiographic axial spondyloarthritis

2.1 Upadacitinib (RINVOQ, AbbVie) is indicated for 'the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs)'.

2.2 The dosage schedule is available in the summary of product characteristics for upadacitinib.

2.3 The list price is £805.56 per 28‑tablet pack, with each tablet containing 15 mg of upadacitinib (excluding VAT; BNF online, accessed November 2022). The annual cost of treatment with one 15‑mg tablet per day is £10,501.05 (excluding VAT; BNF online, accessed November 2022).

2.4 The company has a commercial arrangement. This makes upadacitinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.